Gilead Reports Phase 3 extension Data for Navitoclax in Lupus nephritis

Gilead today announced Phase 3 extension results for Navitoclax in patients with Lupus nephritis. The study demonstrated that Navitoclax achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Lupus nephritis and support the continued development of Navitoclax in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Navitoclax was consistent with previous observations, with no new safety signals identified.